BPC-157 vs Larazotide
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It has been extensively studied in animal models for tissue repair, gastroprotection, and tendon/ligament/muscle healing. Important: essentially all efficacy data are preclinical (rodent), there are no completed published human efficacy trials, and it is prohibited in sport by WADA.
Full profileLarazotide
Larazotide (AT-1001) is a synthetic octapeptide that acts as a tight junction regulator — it competitively blocks zonulin, the primary physiological driver of intestinal permeability ('leaky gut'). It is one of the few compounds studied in human clinical trials specifically for tight junction dysfunction, with Phase 2 data in celiac disease demonstrating reduced intestinal permeability and symptom improvement even in the presence of ongoing gluten exposure.
Full profile| BPC-157 | Larazotide | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Body Protection Compound 157, PL 14736, Pentadecapeptide BPC 157 | Larazotide acetate, AT-1001, INN-202 |
| Evidence | Preclinical only | FDA-approved |
| Dosing range | 200mcg–1000mcg mcg, once or twice daily | 0.25mg–1mg mg, 3x daily (before meals) |
| Administration | Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols) | Oral (capsule), Subcutaneous injection (research use) |
| Key side effects | Nausea (rare, typically at higher doses), Dizziness / lightheadedness shortly after injection (uncommon, anecdotal), Injection site redness or irritation, Human safety profile is not established — no controlled human trials | Headache (most commonly reported adverse event in trials), Nausea (mild), Generally well-tolerated — adverse event rate similar to placebo in clinical trials |
| Cited sources | 6 references | 3 references |
Key differences
- Evidence level differs: BPC-157 is preclinical only, while Larazotide is fda-approved.
- Administration: BPC-157 — Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols); Larazotide — Oral (capsule), Subcutaneous injection (research use).
- Dosing units differ: BPC-157 is dosed in mcg, Larazotide in mg — they operate at different scales.
- Frequency: BPC-157 is typically once or twice daily; Larazotide is 3x daily (before meals).
- Research depth: this profile cites 6 sources for BPC-157 vs 3 for Larazotide.
How each works
BPC-157
Preclinical rodent and in-vitro studies — predominantly from the Sikiric group in Zagreb, with mechanistic angiogenesis work from Pang's group in Taiwan — report accelerated healing of tendon, ligament, muscle, and gut tissue. Proposed mechanisms include modulation of the nitric oxide (NO) system, promotion of angiogenesis via the VEGFR2–Akt–eNOS pathway, upregulation of growth factor signaling, and effects along the gut–brain axis. Despite a large and internally consistent animal literature, BPC-157 has no completed human clinical efficacy trials and is an unapproved drug.
Larazotide
Zonulin upregulation disrupts the tight junction proteins occludin and claudin, allowing paracellular passage of antigens, LPS, and inflammatory triggers into systemic circulation. Larazotide acts as a tight junction agonist by competitively displacing zonulin from its receptor and directly stabilizing tight junction complexes. The Phase 2b CeD trial (N=342) showed larazotide reduced the ratio of lactulose/mannitol (L/M ratio, standard intestinal permeability marker) and improved GI symptom scores versus placebo in actively-challenged celiac patients.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.